What the FDA labels say about taking them together
Sofosbuvir/velpatasvir/voxilaprevir and tenofovir disoproxil
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names tenofovir disoproxil in its drug interactions section, and tenofovir disoproxil's label names sofosbuvir/velpatasvir/voxilaprevir too. The sofosbuvir/velpatasvir/voxilaprevir label: “Monitor for tenofovir-associated adverse reactions in patients receiving VOSEVI concomitantly with a regimen containing tenofovir DF. Refer to the prescribing information of the tenofovir DF-containing product for …”
Check it at the source: the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.); the tenofovir disoproxil FDA label on DailyMed (effective June 7, 2024, Aurobindo Pharma Limited).
What does the sofosbuvir/velpatasvir/voxilaprevir label say about tenofovir disoproxil?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: tenofovir disoproxil fumarate (tenofovir DF); Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ tenofovir; Clinical Effect/Recommendation: Monitor for tenofovir-associated adverse reactions in patients receiving VOSEVI concomitantly with a regimen containing tenofovir DF. Refer to the prescribing information of the tenofovir DF-containing product for recommendations on renal monitoring.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
What does the tenofovir disoproxil label say about sofosbuvir/velpatasvir/voxilaprevir?
Tenofovir disoproxil label, drug interactionsHepatitis C Antiviral Agents: sofosbuvir/velpatasvir sofosbuvir/velpatasvir/ voxilaprevir ledipasvir/sofosbuvir ↑ tenofovir Monitor patients receiving tenofovir disoproxil fumarate concomitantly with EPCLUSA ® (sofosbuvir/velpatasvir) for adverse reactions associated with TDF.
Viread label (Gilead Sciences, Inc., February 18, 2025), drug interactionsNamed in a table that the FDA label file prints without its column breaks; the full label shows the table.
Source: FDA drug label (Viread, NDA021356), Gilead Sciences, Inc., effective February 18, 2025 (SPL set 33fd6418-fbdc-42ca-a50d-ce2a476a5418), via openFDA
Source: FDA drug label (Tenofovir Disoproxil Fumarate), Aurobindo Pharma Limited, effective June 7, 2024 (SPL set a75c6be8-3719-4bb3-8a9e-06e5254d2a82), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Sofosbuvir/velpatasvir/voxilaprevir | Tenofovir disoproxil | |
|---|---|---|
| Labeled for | Hepatitis C | HIV, Hepatitis B |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.294 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once